{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:54:39Z","timestamp":1754146479385,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.7759\/cureus.88219","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:36:17Z","timestamp":1752834977000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Control of Chemotherapy-Induced Breakthrough Hemolysis With Ravulizumab in a Patient With Paroxysmal Nocturnal Hemoglobinuria During Carboplatin-Pemetrexed Treatment for Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Atsushi","family":"Takahata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000540474","article-title":"Paroxysmal nocturnal hemoglobinuria, pathophysiology, diagnostics, and treatment","volume":"51","author":"Panse JP","year":"2024","unstructured":"Panse JP, H\u00f6chsmann B, Schubert J. Paroxysmal nocturnal hemoglobinuria, pathophysiology, diagnostics, and treatment. Transfus Med Hemother. 2024, 51:310-20. 10.1159\/000540474","journal-title":"Transfus Med Hemother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236877","article-title":"Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Brodsky RA","year":"2021","unstructured":"Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al.. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021, 106:230-7. 10.3324\/haematol.2019.236877","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang JC","year":"2024","unstructured":"Yang JC, Lee DH, Lee JS, et al.. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol. 2024, 42:4029-39. 10.1200\/JCO.23.02747","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2587597","article-title":"Prolonged remission of cancer of unknown primary following initiation of eculizumab therapy for paroxysmal nocturnal hemoglobinuria","volume":"2019","author":"Lim MY","year":"2019","unstructured":"Lim MY, Volmar KE, Key NS. Prolonged remission of cancer of unknown primary following initiation of eculizumab therapy for paroxysmal nocturnal hemoglobinuria. Case Rep Hematol. 2019, 2019:2587597. 10.1155\/2019\/2587597","journal-title":"Case Rep Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5539\/cco.v2n1p1","article-title":"An unusual case of a hemolytic crisis associated with the initiation of an aromatase inhibitor in a patient with known history of paroxysmal nocturnal hemoglobinuria","volume":"2","author":"Sikuyayenga M","year":"2013","unstructured":"Sikuyayenga M, Karlin N. An unusual case of a hemolytic crisis associated with the initiation of an aromatase inhibitor in a patient with known history of paroxysmal nocturnal hemoglobinuria. Cancer Clin Oncol. 2013, 2:1-4. 10.5539\/cco.v2n1p1","journal-title":"Cancer Clin Oncol"},{"key":"ref6","article-title":"Development of paroxysmal nocturnal hemoglobinuria after chemotherapy","volume":"15","author":"Hakim F","year":"1996","unstructured":"Hakim F, Childs R, Balow J, et al.. Development of paroxysmal nocturnal hemoglobinuria after chemotherapy. Blood. 1996, 15:4725-6.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40852-3","article-title":"Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models","volume":"14","author":"Porter LH","year":"2023","unstructured":"Porter LH, Zhu JJ, Lister NL, et al.. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nat Commun. 2023, 14:5346. 10.1038\/s41467-023-40852-3","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0311","article-title":"Chemotherapy enriches for proinflammatory macrophage phenotypes that support cancer stem-like cells and disease progression in ovarian cancer","volume":"4","author":"Cruz LS","year":"2024","unstructured":"Cruz LS, Robinson M, Stevenson D, et al.. Chemotherapy enriches for proinflammatory macrophage phenotypes that support cancer stem-like cells and disease progression in ovarian cancer. Cancer Res Commun. 2024, 4:2638-52. 10.1158\/2767-9764.CRC-24-0311","journal-title":"Cancer Res Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.776879","article-title":"The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis","volume":"12","author":"Fuentelsaz-Romero S","year":"2021","unstructured":"Fuentelsaz-Romero S, Barrio-Alonso C, Garc\u00eda Campos R, et al.. The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis. Front Immunol. 2021, 12:776879. 10.3389\/fimmu.2021.776879","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee JW","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al.. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019, 133:530-9. 10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj AG","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al.. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019, 133:540-9. 10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2017.11.023","article-title":"Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment","volume":"85","author":"Ajona D","year":"2019","unstructured":"Ajona D, Ortiz-Espinosa S, Pio R. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin Cell Dev Biol. 2019, 85:153-63. 10.1016\/j.semcdb.2017.11.023","journal-title":"Semin Cell Dev Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00954","article-title":"Targeting the complement pathway as a therapeutic strategy in lung cancer","volume":"10","author":"Kleczko EK","year":"2019","unstructured":"Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the complement pathway as a therapeutic strategy in lung cancer. Front Immunol. 2019, 10:954. 10.3389\/fimmu.2019.00954","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201703-0660OC","article-title":"Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects","volume":"197","author":"Ajona D","year":"2018","unstructured":"Ajona D, Zandueta C, Corrales L, et al.. Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018, 197:1164-76. 10.1164\/rccm.201703-0660OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani A","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017, 14:399-416. 10.1038\/nrclinonc.2016.217","journal-title":"Nat Rev Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0250","article-title":"The C5a\/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response","volume":"13","author":"Senent Y","year":"2025","unstructured":"Senent Y, Rem\u00edrez A, Rep\u00e1raz D, et al.. The C5a\/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response. Cancer Immunol Res. 2025, 13:384-99. 10.1158\/2326-6066.CIR-24-0250","journal-title":"Cancer Immunol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188351","article-title":"The complement system and kidney cancer: pathogenesis to clinical applications","volume":"135","author":"Aalinkeel R","year":"2025","unstructured":"Aalinkeel R, Quigg RJ, Alexander J. The complement system and kidney cancer: pathogenesis to clinical applications. J Clin Invest. 2025, 135:e188351. 10.1172\/JCI188351","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S326352","article-title":"By increasing the expression and activation of STAT3, sustained C5a stimulation increases the proliferation, migration, and invasion of RCC cells and promotes the growth of transgrafted tumors","volume":"13","author":"Zheng JM","year":"2021","unstructured":"Zheng JM, Zhou HX, Yu HY, Xia YH, Yu QX, Qu HS, Bao JQ. By increasing the expression and activation of STAT3, sustained C5a stimulation increases the proliferation, migration, and invasion of RCC cells and promotes the growth of transgrafted tumors. Cancer Manag Res. 2021, 13:7607-21. 10.2147\/CMAR.S326352","journal-title":"Cancer Manag Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529184","article-title":"The role of complement in tumor immune tolerance and drug resistance: a double-edged sword","volume":"16","author":"Yang R","year":"2025","unstructured":"Yang R, Fu D, Liao A. The role of complement in tumor immune tolerance and drug resistance: a double-edged sword. Front Immunol. 2025, 16:1529184. 10.3389\/fimmu.2025.1529184","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.150","article-title":"Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach","volume":"5","author":"Hussain N","year":"2022","unstructured":"Hussain N, Das D, Pramanik A, Pandey MK, Joshi V, Pramanik KC. Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach. Cancer Drug Resist. 2022, 5:317-27. 10.20517\/cdr.2021.150","journal-title":"Cancer Drug Resist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388601-successful-control-of-chemotherapy-induced-breakthrough-hemolysis-with-ravulizumab-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-during-carboplatin-pemetrexed-treatment-for-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:36:17Z","timestamp":1752834977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388601-successful-control-of-chemotherapy-induced-breakthrough-hemolysis-with-ravulizumab-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-during-carboplatin-pemetrexed-treatment-for-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.88219","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}